Shareholders Foundation, Inc.

BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) Investor Lawsuit Deadline on April 6

A Deadline is coming up on April 6, 2012 in lawsuit for investors in BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) and NASDAQ:BPAX stockholders should contact the Shareholders Foundation.


San Diego, CA -- (SBWIRE) -- 03/14/2012 -- A deadline is coming up on April 6, 2012 in the lawsuit filed for investors of BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) over alleged Securities Laws Violations by BioSante Pharmaceuticals, Inc. for allegedly issuing false and misleading statements.

Investors with a substantial investment in BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) shares between February 12, 2010 and December 15, 2011, should get active before the Deadline that is coming up on April 6, 2012 and should contact the Shareholders Foundation at mail(at) or call +1(858) 779 - 1554.

According to the complaint filed in the U.S. District Court for the Northern District of Illinois the plaintiff alleges on behalf of all persons or entities who purchased or otherwise acquired the securities of BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) between February 12, 2010 and December 15, 2011, that BioSante Pharmaceuticals, along with its Chief Executive Officer violated the Securities and Exchange Act of 1934.

Specifically, the plaintiff alleges that the defendants issued a series of materially false and misleading statements to investors about LibiGel's commercial viability, effectiveness, and market potential that caused shares of BioSante Pharmaceuticals to trade at artificially high prices between February 12, 2010 and December 15, 2011.

On December 14, 2011, BioSante Pharmaceuticals, Inc announced the results from LibiGel Efficacy Trials. BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) said that the initial analysis of the data from these trials shows that the trials did not meet the co-primary or secondary endpoints. BioSante's president & CEO said that they are “very disappointed by the Phase III LibiGel efficacy trial results.”

Shares of BioSante Pharmaceuticals, Inc. (Public, NASDAQ:BPAX) fell from $2.50 on December 14, 2011, to $0.48 per share on December 15, 2011.

NASDAQ:BPAX shares closed on December 19, 2011 as low as $0.38 per share.

Those who purchased shares of BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX), have certain options and should contact the Shareholders Foundation.

Shareholders Foundation, Inc.
Joelle Day
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739